Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CollaGenex Periostat Lawsuit Hinges On FDA “Antibiotic” Determination

Executive Summary

A federal judge must determine whether CollaGenex' Periostat is properly classified as an "antibiotic" after preliminarily enjoining FDA from approving generic versions of doxycycline hyclate 20 mg
Advertisement

Related Content

CollaGenex, URL/Mutual Settle Periostat Litigation; FDA Lawsuit Continues
CollaGenex, URL/Mutual Settle Periostat Litigation; FDA Lawsuit Continues
Periostat litigation settled
Periostat litigation settled
Ribavirin ANDAs Still Waiting For FDA; Other Generic Issues Have Priority
Ribavirin ANDAs Still Waiting For FDA; Other Generic Issues Have Priority
CDER Freedom-Of-Information Staff Gets A Boost: 11 New Positions
CDER Freedom-Of-Information Staff Gets A Boost: 11 New Positions
Advertisement
UsernamePublicRestriction

Register

PS042186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel